C. Jeffrey Dekker - 08 Dec 2022 Form 4 Insider Report for ARCA biopharma, Inc. (ORKA)

Role: Chief Financial Officer
Signature: /s/ C. Jeffrey Dekker
Issuer symbol: ORKA
Transactions as of: 08 Dec 2022
Net transactions value: $0
Form type: 4
Filing time: 09 Dec 2022, 15:30:19 UTC
Previous filing: 16 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABIO	Common Stock	Award	$0	+40,000		$0.000000	40,000	08 Dec 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares issued as restricted stock units (an "RSU") under the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The RSUs vest one year from December 8, 2022, subject to continuing employment with the Company through that date. In the event of a change in control of the Issuer or the grantee's involuntary termination without cause or by the grantee for good reason, 100% of the unvested RSUs shall become fully and immediately vested upon the closing date of such change in control or such involuntary termination date, respectively (to the extent such unvested RSUs have not yet then vested).

Content

Represents shares issued as restricted stock units (an "RSU") under the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The RSUs vest one year from December 8, 2022, subject to continuing employment with the Company through that date. In the event of a change in control of the Issuer or the grantee's involuntary termination without cause or by the grantee for good reason, 100% of the unvested RSUs shall become fully and immediately vested upon the closing date of such change in control or such involuntary termination date, respectively (to the extent such unvested RSUs have not yet then vested).